Recommended drug therapies for inflammatory bowel disease

White, Christopher; Thakor, Amit; Goel, Rishi

doi:10.1002/psb.1701

Cited by 2 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBD is characterized by chronic inflammation of the GI tract with periods of disease progression and remission. During relapse periods (i.e., disease activity), patients often present diarrhea, coupled with nausea, weight loss, fever, and abdominal pain 83 . However, IBD pathophysiology is not entirely clear with a multifactorial etiology, influenced by individual genetic susceptibility, the external environment, internal gut microbiota, and the host immune response 84 .…”

Section: The Microbiological Aspectmentioning

confidence: 99%

Update on fecal microbial transplantation for the treatment of inflammatory bowel disease

Llir�s¹,

Lluans�²,

Bah�³

et al. 2021

JIMIDS

View full text Add to dashboard Cite

The human microbiome, or the plethora of microorganisms symbiotically coexisting with us, plays a crucial role in both the health and the disease of the host. Interestingly, the gut microbiome has been identified as unique and characteristic to any human being, with common functionalities, even common evolutionary trends with age. A stable, rich, and diverse gut microbiome has been associated to a healthy intestinal state and clinical outcome, thus unbalanced gut microbial composition (i.e., dysbiosis) has been associated with detrimental outcomes, such as inflammation or altered metabolism. To reverse the negative effects of dysbiotic microbiome, fecal microbial transplantation (FMT) has been proposed as a successful strategy (initially demonstrated for Clostridioides difficile recurrent infections). However, several attempts have been performed to use FMT to overcome other recalcitrant dysbiotic situations, especially for the case of inflammatory bowel diseases (IBD). In this sense, supportive data are scarce and focused mainly in ulcerative colitis where some early results set a trend toward some clinical effect. Nonetheless, before FMT may be supported for its extensive use in clinics, besides more robust studies, there is a need to standardize and optimize the procedure with special attention to the matching of donor/recipient. We review current state of the art in FMT in the IBD clinical field with special attention to donor selection, FMT preparation, and patient matching.

show abstract

Section: The Microbiological Aspectmentioning

confidence: 99%

Update on fecal microbial transplantation for the treatment of inflammatory bowel disease

Llir�s¹,

Lluans�²,

Bah�³

et al. 2021

JIMIDS

View full text Add to dashboard Cite

show abstract

“…IBD is characterized by chronic inflammation of the gastrointestinal tract, as well as the periodicity of disease progression and remission. During disease activity, patients are likely to present with diarrhoea, coupled with nausea, loss of weight, anepithymia, fever, and celialgia (White et al, 2018). However, the precise pathophysiology is not entirely clear and the aetiology is multifactorial, influenced by individual genetic susceptibility, the external environment, internal gut microbiota, and the host immune response (Zhou et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Tan

Shen

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Fecal microbiota transplantation (FMT) has successfully been applied for the treatment of recurrent Clostridioides difficile infection (CDI), which has led to studies on its application to other gastrointestinal diseases and extraintestinal diseases associated with gut microbiota dysbiosis. Recently, the results of FMT for patients with inflammatory bowel disease (IBD) have been encouraging. However, studies have not fully clarified the clinical application of this emerging therapy. Here, we aimed to review the current knowledge in this fast-growing field and characterize the effectiveness, safety and mechanisms of FMT for the treatment of IBD patients.

show abstract

Recommended drug therapies for inflammatory bowel disease

Cited by 2 publications

References 21 publications

Update on fecal microbial transplantation for the treatment of inflammatory bowel disease

Update on fecal microbial transplantation for the treatment of inflammatory bowel disease

Fecal Microbiota Transplantation for the Treatment of Inflammatory Bowel Disease: An Update

Contact Info

Product

Resources

About